Use of a chimeric monoclonal anti‐CD4 antibody in patients with refractory rheumatoid arthritis

Arthritis & Rheumatism

Volumn 36, Issue 3, 1993, Pages 307-318

  Moreland, Larry W ^a,b   Bucy, Ralph P ^a,b   Tilden, Arabella ^a,b   Pratt, Parks W ^a,b   Lobuglio, Albert F ^a,b   Khazaeli, M ^a,b   Everson, Michael P ^a,b   Daddona, Peter ^a,b   Ghrayeb, John ^a,b   Kilgarriff, Charles ^a,b   Sanders, Martin E ^a,b   Koopman, William J ^a,b  

^a The University of Alabama at Birmingham   (United States)

^b CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUROTHIOMALATE; AZATHIOPRINE; CD4 ANTIGEN; CHIMERIC ANTIBODY; HYDROXYCHLOROQUINE; INTERLEUKIN 6; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; OKT 4; PENICILLAMINE; PREDNISONE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG FEVER; DRUG SAFETY; FEMALE; HUMAN; HYPOTENSION; IMMUNOGENICITY; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE PROLIFERATION; MALAISE; MALE; MYALGIA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE SUBPOPULATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CD4-POSITIVE T-LYMPHOCYTES; CHIMERA; DRUG TOLERANCE; FEMALE; HUMAN; IMMUNOTHERAPY; LEUKOCYTE COUNT; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; T-LYMPHOCYTES, SUPPRESSOR-EFFECTOR; TREATMENT OUTCOME;

EID: 0027503243     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.1780360304     Document Type: Article

References (42)

1. Rheumatoid arthritis: pathophysiology and implications for therapy
2. Predominantly T‐cell infiltrate in rheumatoid synovial membrane
3. Ia+ T cells in synovial fluid and tissue of patients with rheumatoid arthritis
4. Association of the B‐cell alloantigen DRw4 with rheumatoid arthritis
5. Association of HLA‐Aw31 and HLA‐DR1 with adult rheumatoid arthritis
6. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis
7. HLA genes associated with rheumatoid arthritis: identification of susceptibility alleles using specific oligonucleotide probes
8. Rheumatoid arthritis complicated by infection with human immunodeficiency virus and the development of Sjögren's syndrome
9. Lymphocyte involvement in rheumatoid arthritis: studies during thoracic duct drainage
10. Prevention of type II collagen‐induced arthritis by in vivo treatment with anti‐L3T4
11. 1 mice by treatment with monoclonal antibody to L3T4
12. Immunotherapy for myasthenia gravis: a murine model
13. Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T‐cell subset marker
14. Preventive effect of monoclonal anti‐L3T4 antibody on development of diabetes in NOD mice
15. Suppression in murine experimental autoimmune thyroiditis: in vivo inhibition of CD4+ T‐cell‐mediated resistance by a nondepleting rat CD4 monoclonal antibody
16. Inhibition of autoimmune uveitis by anti‐CD4 antibody
17. Monoclonal anti‐CD4 in arthritis
18. Therapeutic use of monoclonal anti‐CD4 antibody in rheumatoid arthritis
19. Treatment of rheumatoid arthritis with monoclonal CD4 antibody M‐T151: clinical results and immunopharmacologic effects in an open study, including repeated administration
20. Treatment of rheumatoid arthritis with an anti‐CD4 monoclonal antibody
21. Anti‐CD4 treatment of patients with rheumatoid arthritis I. Effect on clinical course and circulating T‐cells
22. Human anti‐mouse antibody response induced by anti‐CD4 monoclonal antibody therapy in patients with rheumatoid arthritis
23. Immunological effects of high dose administration of anti‐CD4 antibody in rheumatoid arthritis patients
24. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response
25. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
26. Therapeutic criteria in rheumatoid arthritis
27. In vitro efficacy of a mouse/human chimeric CD4 antibody: functional contributions of isotype and Fc (abstract)
28. Molecular forms of IgA rheumatoid factor in serum and synovial fluid of patients with rheumatoid arthritis
29. Quantitation of mouse monoclonal antibody and human anti‐mouse antibody response in serum of patients
30. IgA rheumatoid factor synthesis by dissociated synovial cells: characterization and relationship to IgM rheumatoid factor synthesis
31. Occurrence of IgG and IgA rheumatoid factors prior to onset of rheumatoid arthritis (abstract)
32. Preexisting human antimurine immunoglobulin reactivity due to polyclonal rheumatoid factors
33. Frequent anti‐V region immune response to mouse B72.3 monoclonal antibody
34. Monitoring and complications of monoclonal therapy: complications and monitoring of OKT3 therapy
35. Interleukin‐6 as an endogenous pyrogen: induction of prostaglandin E2 in brain but not in peripheral blood mononuclear cells
36. Anti‐CD4 treatment with chimeric monoclonal antibody results in prolonged CD4+ cell depression (abstract)
37. Chimeric monoclonal antibody cM‐T412 induces a long lasting CD4 cell depletion in rheumatoid arthritis patients (abstract)
38. Clinical status of rheumatoid arthritis patients 18 months after treatment with chimeric anti‐CD4 antibody (abstract)
39. Radioimmunotargeting of ovarian cancer: using different forms of the chimeric monoclonal antibody MOv18 in the same patient (abstract)
40. 131I‐chimeric mouse/human B72.3 (human γ4) monoclonal antibody in humans
41. A phase I trial of the chimeric anti‐GD2 monoclonal antibody ch14.18 in patients with malignant melanoma